Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia

Posted On March 1st, 2004

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia
The adoption of Gleevec, a pioneering drug in the treatment of CML, highlights challenges and opportunities in bringing drugs treating rare diseases to market.

View more publications

NEHI Member Spotlight

See our full member directory

Back to Top